| IPO Listing At | BSE, NSE |
| IPO Issue Type | Book Build Issue |
| Issue Size | ₹846.25 Cr |
| Offer for Sale | ₹846.25 Cr |
| Face Value | βΉ2 Per Equity Share |
| Price Band | βΉ420.00-441.00 per share |
| Discount | Retail: 0.00 |
| BSE Code | 544293 |
| NSE Code | SURAKSHA |
| Registrar | Kfin Technologies Ltd. |
| Lead Managers | ICICI Securities Ltd. |
Disclaimer: GMP is sourced from grey market dealers and is indicative only. Always conduct your own due diligence.
* Allotment, Refund, Demat Credit & Listing dates are tentative and subject to change.
Minimum bid: 34 shares and in multiples thereof
Incorporated in 2005, Suraksha Diagnostic Limited offers pathology, radiology testing and medical consultancy services. The company has a central reference laboratory with 8 satellite laboratories and 215 customer touchpoints, including 49 diagnostic centres and 166 sample collection centres as of June 30, 2024, across West Bengal, Bihar, Assam, and Meghalaya.
The company offers its customers online and offline medical consultation services under one roof via 44 diagnostic centres, which house 120 polyclinics with more than 750 doctors.
The operation of the diagnostic centres is supported by the technology platforms and systems that the company uses to streamline, such as its Laboratory Information Management System ("LIMS"), its fully integrated Radiology Information System ("RIS"), its Picture Archive Communication System ("PACS") and its Enterprise Resource Planning System ("ERP").
The company offers vaccination services and customized testing packages for disease prediction/early detection. The company uses digital pathology and artificial intelligence to generate blood tests. All radiology reporting is done through a digital platform that allows cases to be reported from all diagnostic centres, significantly reducing turnaround time.
Competitive Strengths are:
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (βΉ Cr.) |
|---|---|---|
| 1 | The Company will not receive any proceeds from the Offer (βOffer Proceedsβ) and all such proceeds (net of any Offer related expenses to be borne by the Selling Shareholders) will go to the Selling Shareholders. |
| Period Ended | 30 Jun 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 314.20 | 300.21 | 281.20 | 275.96 |
| Total Income | 61.85 | 222.26 | 193.69 | 225.77 |
| Profit After Tax | 7.67 | 23.13 | 6.07 | 20.82 |
| NET Worth | 187.05 | 179.41 | 155.93 | 145.84 |
| Reserves and Surplus | 176.80 | 170.88 | 147.40 | 137.31 |
| Total Borrowing | 7.57 | 8.64 | 14.01 | 19.03 |
| Amount in ₹ Crore | ||||
| KPI | Mar 31, 2024 |
|---|---|
| ROE | 14.09% |
| ROCE | 21.46% |
| Debt / Equity | 0.20% |
| RoNW | 14.09% |
| PAT Margin | 10.57% |
| Price to Book Value | 13.10 |
| Metric | Pre IPO | Post IPO |
|---|---|---|
| EPS (βΉ) | 4.44 | 5.89 |
| P/E (x) | 99.31 | 74.89 |
| Promoter Holding | 61.07% | 48.78% |
| Market Cap | βΉ2296.76 Cr. | |